Tech Transfer eNews Blog

Lab1636 announces first project to turn Harvard research into novel therapeutics


By Jesse Schwartz
Published: January 15th, 2020

Lab1636, a research and development partnership between Harvard University and the investment firm Deerfield Management Company, has announced its first project aimed at turning Harvard research into novel therapeutics.

The project will focus on the work of David Ginty, a professor at Harvard Medical School, and Lauren Orefice, a postdoctoral researcher in Ginty’s lab. Together they have identified specific compounds that may lead to a treatment for touch hypersensitivity related to autism disorders.

Lab 1636 is now poised to validate and expand upon their research in order to accelerate the compounds through late-stage preclinical development.

“It’s exciting to see discoveries made in my lab being propelled into therapeutic development, where they can benefit from the medicinal chemistry expertise and clinical expertise of other groups,” says Ginty. “The resources at Harvard to support translational biomedical innovation were really instrumental in helping us advance this work to a jumping-off point, and I’m hopeful that further development and clinical testing of the results could make a significant and lasting difference in the lives of patients.”

James E. Flynn, managing partner at Deerfield, comments, “This is an important milestone for Lab 1636 and potentially for people suffering from tactile hypersensitivity. We look forward to continued progress in professor Ginty’s novel work and other exciting developments on the horizon at Harvard.”

Source: Business Wire

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment